Estrogenic suppression by different administration schedules of goserelin depot for treatment of endometriosis.

Author: FortiG, MaginiA, MassiG B, PellegriniS, SerioM, TavellaK

Paper Details 
Original Abstract of the Article :
Eighteen patients affected by laparoscopically confirmed endometriosis were randomly assigned to three different schedules of treatment with gonadotropin-releasing hormone agonist (GnRH-a) (goserelin depot formulation 3.6 mg) every 28 days for 6 months. Six women received the first implant in early ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/BF03348925

データ提供:米国国立医学図書館(NLM)

Estrogen Suppression: A Key to Managing Endometriosis

Endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, can cause pain and infertility. This study focuses on the use of a gonadotropin-releasing hormone agonist (GnRH-a), goserelin depot, to effectively manage endometriosis by suppressing estrogen levels. The study highlights the importance of finding the right dosage and schedule for GnRH-a treatment to achieve optimal results. The researchers compared different administration schedules and found that a luteal phase administration led to more effective estrogen suppression.

GnRH-a: A Potential Game Changer for Endometriosis

The findings suggest that GnRH-a, particularly when administered in the luteal phase, can effectively reduce the severity of endometriosis, potentially improving the quality of life for women affected by this condition. This study provides valuable insights for physicians seeking to manage endometriosis, helping them to optimize treatment strategies and achieve better patient outcomes.

Benefits of GnRH-a Treatment

By reducing estrogen levels, GnRH-a can alleviate the pain and discomfort associated with endometriosis, potentially enabling women to lead more active and fulfilling lives. The study's findings highlight the need for physicians to stay abreast of the latest advancements in endometriosis management, utilizing evidence-based therapies to provide the best possible care for their patients. This study is a beacon of hope in the field of endometriosis research, guiding us toward better treatment options and ultimately improved patient well-being.

Dr. Camel's Conclusion

Endometriosis, like a persistent desert mirage, can be a frustrating and painful condition. However, this study shows that GnRH-a, when used strategically, can effectively combat endometriosis by suppressing estrogen levels. This research is a valuable tool in our quest to find solutions for women suffering from this condition, offering hope for a future where endometriosis is effectively managed, and women can enjoy a healthy and fulfilling life.

Date :
  1. Date Completed 1994-05-04
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

8144850

DOI: Digital Object Identifier

10.1007/BF03348925

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.